PF-Atlas › Clinical Trials › NCT00052052

An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis

interferon-gamma 1b · Phase 2

Registry ID
NCT00052052
Phase
Phase 2
Status
Completed
Drug / intervention
interferon-gamma 1b
Sponsor
InterMune
Start
2002-09
Enrollment
210
Locations
1

About this trial

Study GIPF-004 is an open-label, multicenter study that will enroll approximately 250 patients who complete Protocol GIPF-001. The purpose of this study is to assess the safety and efficacy of continued IFN-gamma 1b therapy in this well-defined cohort of patients for up to 48 weeks.

View NCT00052052 on ClinicalTrials.gov →

Explore related

All interferon-gamma 1b trialsAll IPF trials

Related trials

Interferon-gamma 1b — NCT00047658Interferon-gamma 1b — NCT00047645
Medical disclaimer. This page summarizes public trial data for NCT00052052 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.